We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
A Threefold Dose Intensity Treatment With Ifosfamide, Carboplatin, and Etoposide for Patients With Small Cell Lung Cancer: A Randomized Trial.
- Authors
Leyvraz, Serge; Pampallona, Sandro; Martinelli, Giovanni; Ploner, Ferdinand; Perey, Lucien; Aversa, Savina; Peters, Solange; Brunsvig, Paal; Montes, Ana; Lange, Andrzej; Yilmaz, Ugur; Rosti, Giovanni
- Abstract
The dose intensity of chemotherapy can be increased to the highest possible level by early administration of multiple and sequential high-dose cycles supported by transfusion with peripheral blood progenitor cells (PBPCs). A randomized trial was performed to test the impact of such dose intensification on the long-term survival of patients with small cell lung cancer (SCLC). Patients who had limited or extensive SCLC with no more than two metastatic sites were randomly assigned to high-dose (High, n = 69) or standard-dose (Std, n = 71) chemotherapy with ifosfamide, carbo- platin, and etoposide (ICE). High-ICE cycles were supported by transfusion with PBPCs that were collected after two cycles of treatment with epidoxorubicin at 150 mg/m2, paclitaxël at 175 mg/m2, and filgrastim. The primary outcome was 3-year survival. Comparisons between response rates and toxic effects within subgroups (limited or extensive disease, liver metastases or no liver metastases, Eastern Cooperative Oncology Group performance status of 0 or 1, normal or abnormal lactate dehydrogenase levels) were also performed. Median relative dose intensity in the High-ICE arm was 293% (range = 174%-392%) of that in the Std-ICE arm. The 3-year survival rates were 18% (95% confidence interval [CI] = 10% to 29%) and 19% (95% Cl = 11% to 30%) in the High-ICE and Std-ICE arms, respectively. No differences were observed between the High-ICE and Std-ICE arms in overall response (n = 54 [78%, 95% Cl = 67% to 87%] and n = 48 [68%, 95% Cl = 55% to 78%], respectively) or complete response (n = 27 [39%, 95% CI = 28% to 52%] and n = 24 [34%, 95% CI = 23% to 46%], respectively). Subgroup analyses showed no benefit for any outcome from High- ICE treatment. Hematologic toxicity was substantial in the Std-ICE arm (grade 2 3 neutropenia, n = 49 [70%]; anemia, n = 17 [25%]; thrombopenia, n = 17 [25%]), and three patients (4%) died from toxicity. High- ICE treatment was predictably associated with severe myelosuppression, and five patients (8%) died from toxicity. The long-term outcome of SCLC was not improved by raising the dose intensity of ICE chemotherapy by threefold.
- Subjects
CANCER treatment; SMALL cell lung cancer; CANCER patients; ETOPOSIDE; METASTASIS
- Publication
JNCI: Journal of the National Cancer Institute, 2008, Vol 100, Issue 8, p533
- ISSN
0027-8874
- Publication type
Article
- DOI
10.1093/jnci/djn088